Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
04:21am, Tuesday, 09'th Apr 2024
AbbVie's dividend payout has more than tripled over the past decade, and it could soar much further in the decade ahead. Bristol Myers Squibb offers a juicy 4.7% dividend yield at recent prices.
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
02:31pm, Monday, 08'th Apr 2024
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
01:32pm, Saturday, 06'th Apr 2024
Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain
5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024
09:30am, Saturday, 06'th Apr 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
The 3 Most Undervalued Biotech Stocks to Buy in April 2024
01:54pm, Friday, 05'th Apr 2024
With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one's buck. Fo
U.S. FDA allows expanded use of Bristol Myers' cell therapy
09:14am, Friday, 05'th Apr 2024
The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
10:05am, Thursday, 04'th Apr 2024
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
10:16am, Wednesday, 03'rd Apr 2024
Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
08:58pm, Monday, 01'st Apr 2024
Bristol-Myers Squibb has expected 2024 annual revenue of $45.85B and expected annual earnings per share of $6.83. BMY is currently below its 10-month exponential moving average (EMA), indicating beari
MAI Capital's Grisanti offers 3 buys and a bail: Bristol Myers Squibb, Verizon, Hershey & Boeing
02:25pm, Monday, 01'st Apr 2024
Chris Grisanti, MAI Capital Management chief equity strategist, joins 'The Exchange' to discuss how to trade Bristol Myers Squibb, Verizon, Hershey, and Boeing.
The Bargain Hunter's Dream: 3 Underpriced Stocks Poised for Massive Gains
02:16pm, Monday, 01'st Apr 2024
Three well-known companies stand out among the market's complexity as excellent opportunities for investors looking for significant gains. Each company operates in the broad domains of pharmaceuticals
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
01:51pm, Monday, 01'st Apr 2024
Patients treated with Bristol Myers' (BMY) Zeposia in a phase III study for Crohn's disease did not achieve disease remission.
10 Dividend Growth Stocks: March 2024
03:44am, Monday, 01'st Apr 2024
10 Dividend Growth Stocks: March 2024
The 3 Best Biotech Stocks to Buy in Q2 2024
06:40am, Friday, 29'th Mar 2024
Biotech is an industry full of opportunity. It's also known as one of the riskiest sectors to invest in.
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
04:26pm, Thursday, 28'th Mar 2024
Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.
